Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.
Weeke P, Andersson C, Fosbøl EL, Brendorp B, Køber L, Sharma AM, Finer N, James PT, Caterson ID, Rode RA, Torp-Pedersen C. Weeke P, et al. Among authors: caterson id. BMC Endocr Disord. 2010 Feb 26;10:3. doi: 10.1186/1472-6823-10-3. BMC Endocr Disord. 2010. PMID: 20184783 Free PMC article.
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C; SCOUT Executive Steering Committee; SCOUT investigators. Andersson C, et al. Among authors: caterson id. Metabolism. 2009 Aug;58(8):1109-15. doi: 10.1016/j.metabol.2009.04.003. Epub 2009 Jun 18. Metabolism. 2009. PMID: 19454355 Clinical Trial.
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.
Andersson C, Weeke P, Brendorp B, Køber L, Fosbøl EL, Sharma AM, Finer N, Caterson ID, Rode RA, James PT, Torp-Pedersen C. Andersson C, et al. Among authors: caterson id. Nutr Metab (Lond). 2009 Oct 14;6:42. doi: 10.1186/1743-7075-6-42. Nutr Metab (Lond). 2009. PMID: 19828038 Free PMC article.
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.
Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W, Finer N, Sharma AM, Maggioni AP, Torp-Pedersen C. Andersson C, et al. Among authors: caterson id. Diabetologia. 2012 Sep;55(9):2348-55. doi: 10.1007/s00125-012-2584-3. Epub 2012 May 26. Diabetologia. 2012. PMID: 22638548 Free article. Clinical Trial.
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P; SCOUT Investigators. Maggioni AP, et al. J Cardiovasc Pharmacol. 2008 Nov;52(5):393-402. doi: 10.1097/FJC.0b013e31818713d6. J Cardiovasc Pharmacol. 2008. PMID: 19033818 Clinical Trial.
282 results